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ABSTRACT
Introduction: The aim of this study was to
explore the impact of insulin pump therapy on
diabetes treatment satisfaction and glycemic
control among patients with type 1 diabetes
mellitus (T1DM) in Saudi Arabia.
Methods: A 6-month, prospective study was
conducted among 47 patients (aged
17–24 years) with T1DM who attended the
Insulin Pump Clinic at Prince Sultan Military
Medical City, Riyadh, Saudi Arabia, between
April 2014 and November 2014. The
respondents were purposively and
conveniently selected and were interviewed
using the Arabic version of the Diabetes
Treatment Satisfaction Questionnaire at
baseline, 3, and 6 months. Demographics and
clinical variables including hemoglobin A1c
(HbA1c) were also collected.
Results: The mean (±standard deviation) age of
the study cohort was 19.1 ± 1.93 years. Seventeen
patients were male (36.2%) and 30 were female
(63.8%). Compared to baseline, significant
positive differences were found in treatment
satisfaction among female patients and patients
with long-standing T1DM at 6 months.
Frequency of hyperglycemia and hypoglycemia
declined significantly in female patients at
6 months and in patients who had a shorter
duration of T1DM. Furthermore, significant
positive differences were found in HbA1c levels
among female patients and among those who
had a shorter duration of T1DM compared to
baseline. Both female and male patients and
those with a shorter duration of T1DM showed
a significant decline in insulin necessity at
6 months when compared to baseline.
Conclusion: Although multiple daily injections
is a feasible preference for insulin supply,
insulin pumps should also be considered for
patients with T1DM as it appears to increase
patients’ treatment satisfaction, decrease the
frequency of hypoglycemia, hyperglycemia,
and reduce HbA1c levels.
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INTRODUCTION
Type 1 diabetes mellitus (T1DM) is a chronic
disease, generally diagnosed in children and
adolescents, which needs strict
multidisciplinary treatment over the patient’s
lifetime. Over the last few eras, the incidence of
T1DM has been increasing in many regions of
the world [1, 2]. Studies have reported that the
incidence of T1DM in Saudi Arabia has also
increased over the last 30 years [3]. The
incidence of T1DM in Saudi Arabian children
and adolescents is 109.5 per 100,000, which is
higher than in many developed countries [4, 5].
The imperative purpose of treatment of
T1DM in children and adolescents is to keep
up near-normoglycemia through intensive
insulin therapy, to preclude serious
complications, and to avoid long-standing
macrovascular and microvascular
complications, while facilitating as close to a
normal life as possible [6]. Effective and regular
insulin therapy must therefore be delivered on
the basis of the patient’s necessities, choices,
resources, and the family for the best
management of T1DM [6, 7].
Scientific and technological developments in
insulin pump therapy––or continuous
subcutaneous insulin infusion (CSII) such as
strategy and functionality, advanced features
for calculating insulin doses, providing insulin
and examining data the extensive
dissemination of accrued knowledge and the
desire to succeed glycemic levels as near to the
normal level as possible, have resulted in a
substantial rise in insulin pump use around the
world [8–10]. Compared to multiple daily
injections (MDI), insulin pump treatment is a
more valuable, more effective, and safer method
for maintaining glycemic control, minimizing
diabetes-associated complications, providing
higher flexibility in daily life, and a better
quality of life [8–10].
Despite advances in medical technology and
research documenting their clinical
effectiveness having led to the increased use of
insulin pump therapy worldwide, the use of
insulin pumps in Saudi Arabia is relatively
limited, and there is also limited evidence
regarding their impact on glycemic control
and diabetes treatment satisfaction. Therefore,
the present study aimed to explore the impact
of insulin pump therapy on treatment
satisfaction and glycemic control among
patients with T1DM.
METHODS
Study Design, Setting, and Sampling
A 6-month, prospective study was conducted in
47 patients (aged 17–24 years) with T1DM
registered at the Insulin Pump Clinic, Prince
Sultan Military Medical City (PSMMC), Riyadh,
Saudi Arabia, between April 2014 and
November 2014. The respondents were
purposively and conveniently selected, and
eligible patients (see below) were given
individual patient numbers.
Inclusion and Exclusion Criteria
Patients with T1DM, aged 17–24 years, treated
with MDI therapy for the last 12 months, and
Saudi nationals were included in the study.
Patients who had a history of psychopathology,
cognitive impairment, and those already under
insulin pump treatment were excluded.
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Compliance with Ethics Guidelines
This study was conducted in accordance with
the Helsinki Declaration of 1964, as revised in
2013, and the protocol of this study was
approved by the research ethics committee of
the PSMMC. Patients were informed about the
purpose and methods of the research both
verbally and in written form. Written consent
was obtained from patients before the
completion of study measurement.
Insulin Pump Training
Prior to commencing the insulin pump therapy,
all eligible patients received pre-insulin pump
education and a general introduction to pump
therapy for the Paradigm VeoTM system
(Medtronic MiniMed, Northridge, CA, USA).
All the information used in the training
program, including pamphlets, were in the
patients’ national language (Arabic). In
addition, initial insulin pump training for
those transitioning from MDI therapy and
carbohydrate counting sessions were given.
After initiation of insulin pump therapy, all
patients were in daily contact with the same
pump trainer for the first week, then 3–7
appointments were given for the first month,
and then monthly follow-up visits were
scheduled within the insulin pump clinic
(Diabetes Treatment Center, PSMMC) for the
stabilizing of insulin pump therapy.
Study Measurements
An Arabic version of the Diabetes Treatment
Satisfaction Questionnaire (DTSQ), specifically
designed to measure diabetes treatment
satisfaction, was used. This instrument aims to
assess changes in patient satisfaction related to
therapy modifications, and is also useful for
comparing the level of satisfaction in patients
using different treatment strategies.
The DTSQ is an accurate instrument for
measuring treatment satisfaction in patients
with T1DM [11]. The DTSQ contains eight
health concepts: six questions address general
satisfaction with a score from 0 (very
dissatisfied) to 6 (very satisfied). The entire
score is a sum of the six separate item scores.
A higher overall score specifies a higher
satisfaction with diabetes treatment [11]. Two
questions connected to the occurrence of
hyperglycemic and hypoglycemic events are
assessed independently. Both questions are
measured with a score from 0 (never
experienced) to 6 (most of the time) [11].
Clinical variables including hemoglobin A1c
(HbA1c) and diabetes treatment satisfaction
were collected at baseline, 3, and 6 months.
HbA1c readings were collected from the
patients’ records which are analyzed in the
central lab at PSMMC (COBAS INTEGRA 400
plus/800 analyzers).
Hyperglycemia and Hypoglycemia
All patients involved in the study were advised
to record finger stick blood glucose readings at
least 6–7 times daily and to record these in a
standard self-monitoring blood glucose dairy
that was reviewed and documented to report
any hypoglycemic or hyperglycemia readings.
Hyperglycemia was defined as any blood
glucose value[180 mg/dL ([10 mmol/L) while
hypoglycemia was defined as any blood glucose
value B70 mg/dL (B3.9 mmol/L),
Statistical Analysis
Data analysis was performed using Excel 2010
(Microsoft Corporation, Seattle, WA, USA) and
SPSS version 16 (SPSS Inc., Chicago, IL, USA). In
Diabetes Ther (2015) 6:227–236 229
addition to descriptive analysis, t tests and
Tukey’s post hoc tests were used to look for
differences among the groups. A P value of
\0.05 was considered statistically significant.
RESULTS
Out of the 56 patients recruited, nine failed to
show up at 3 months after the baseline visit or
failed to show at the last visit (6 months) and
were excluded from the study. A total of 47
adolescents continued until the end of the
study and were included in the analysis. The
demographic variables of the study population
are shown in Table 1. The mean [±standard
deviation (SD)] age of the study cohort was
19.1 ± 1.93 years. Seventeen patients were male
(36.2%) and 30 were female (63.8%). The mean
(±SD) duration of diagnosis of T1DM was
8.13 ± 5.3 years. The majority of the patients
were in\20 years age group (70.2%) and more
than 55% of the patients had long-standing
diabetes (C7 years).
The treatment satisfaction of the study
population is shown in Fig. 1. Compared to
baseline, a significant positive difference was
found in treatment satisfaction in female
patients at 6 months (P\0.05). Similarly,
patients with long-standing T1DM expressed
significant improvement in treatment
satisfaction at 6 months (P\0.05).
Compared to baseline, frequency of
hyperglycemia was significantly reduced among
female patients and patients who had a shorter
duration of T1DM at 6 months (P\0.05;
Table 2). Similarly, frequency of hypoglycemia
was also significantly reduced among female
patients and patients who had a shorter duration
of T1DM at 6 months when compared to
baseline (P\0.05; Table 2). However, no
significant differences were observed between
genders and duration of T1DM (P[0.05).
Compared to baseline positive improvements
were observed in necessity of insulin dose among
both genders and those with a shorter duration
of T1DM (P\0.05). No notable differences were
found for body weight within the study
population (Table 2).
Positive differences were found in the HbA1c
levels of both genders, among different patient
age groups, and among patients with different
duration of T1DM. However, compared to
baseline, significant positive differences were
found in HbA1c levels among female patients
and those who had a shorter duration of T1DM
(P\0.05; Fig. 2).
DISCUSSION
In the present prospective study, we found that
insulin pump treatment generally increased
treatment satisfaction among the study
population when compared to MDI treatment.
This is in agreement with previous studies,
where insulin pump therapy has been shown






\20 years 33 70.2





B7 years 21 44.7
[7 years 26 55.3
T1DM type 1 diabetes mellitus
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to have better treatment satisfaction, probably
associated with the insulin pumps’ higher
portability and improved comfort of insulin
dosing [12, 13]. The suspension of insulin
infusion permits for better control over insulin
supply and adjustment of insulin dosing
according to the activity level [12, 13]. It
should be noted that in our study we found a
significant increase in treatment satisfaction
among female patients compared to baseline.
In contrast to our finding, other studies have
found that lower treatment satisfaction is
correlated with being female, using insulin,
and having diabetic complications [14]. This
challenge involves the body image concerns of
young adults. Female patients do not like the
concept of being tethered to the pump via
tubing for the entire day, and they do not want
to worry about where to wear the pump on their
clothing. On the other hand, some female
patients who are more private about their
diabetes do not like the visibility of a pump,
and they do not like having to describe the
pump to others [15]. Similarly, female patients
who are using an insulin pump indicated higher
levels of body frustration and self-
consciousness, while younger patients report
feeling different, lower levels of treatment
satisfaction, and consider pumps to be
unfashionable [15]. However, the positive
findings among our study group may due to
the fact that Saudi girls always use the abaya (a
full-length, sleeveless outer garment) which
covers the whole body except the face, feet,
and hands. This dress code may help girls in
Saudi Arabia to overcome the above-stated
reasons for not wearing insulin pump, when
compared to the Western world.
It is essential to state here that we found
positive decrease in HbA1c levels among both
genders, patients of different ages, and patients
with different duration of T1DM. However, no
significant differences were observed among
these different variables except for female
patients and for those with a shorter duration
of T1DM. There is also a debate concerning the
long-standing usefulness of insulin pump
therapy to lower HbA1c levels and increase
Fig. 1 Impact of insulin pump therapy on treatment satisfaction. Values are presented as mean ± standard deviation.
Groups compared by t test and Tukey’s post hoc test. *P\0.05 considered signiﬁcant. DM diabetes mellitus, yrs years
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Table 2 Impact of insulin pump therapy on frequency of hyperglycemia, hypoglycemia, insulin dose, and body weight
Variables Frequency of hyperglycemia Frequency of hypoglycemia
Baseline 3 months 6 months Baseline 3 months 6 months
Gender
Male 2.30 ± 1.25 2.13 ± 1.21 2.04 ± 1.26 2.48 ± 0.94 2.04 ± 0.87 1.91 ± 0.99
Female 2.42 ± 0.92 1.88 ± 1.07 1.83 ± 1.52* 2.63 ± 0.92 2.20 ± 0.84 1.50 ± 1.40*
Age
\20 years 2.39 ± 1.27 1.91 ± 1.20 1.64 ± 1.44 2.64 ± 1.05 1.97 ± 0.84 1.55 ± 1.09
C20 years 2.29 ± 0.46 2.21 ± 0.95 2.06 ± 1.36 2.36 ± 0.49 2.57 ± 0.75 2.04 ± 1.50
Education
Secondary 2.48 ± 1.22 2.04 ± 1.16 2.15 ± 1.4 2.56 ± 1.08 1.89 ± 0.89 1.52 ± 1.15
College 2.20 ± 0.89 1.95 ± 1.14 1.65 ± 1.35 2.55 ± 0.68 2.50 ± 0.68 1.95 ± 1.35
Duration of T1DM
\7 years 2.62 ± 0.85 1.92 ± 1.09 1.86 ± 1.3* 2.85 ± 0.78 2.23 ± 0.90 1.62 ± 1.32*
C7 years 2.05 ± 1.28 2.10 ± 1.22 2.00 ± 1.41 2.19 ± 0.98 2.05 ± 0.80 1.81 ± 1.16
Overall total 2.36 ± 1.09 2.00 ± 1.14 1.70 ± 1.25 2.55 ± 0.92 2.15 ± 0.85 1.70 ± 1.25
Variables Insulin dose (IU/kg) Body weight (kg)
Baseline 3 months 6 months Baseline 3 months 6 months
Gender
Male 1.31 ± 0.13 1.20 ± 0.20 1.01 ± 0.23* 63.1 ± 6.77 63.2 ± 5.66 64.1 ± 4.99
Female 1.26 ± 0.25 1.17 ± 0.22 1.00 ± 0.16* 57.2 ± 9.32 57.8 ± 6.35 58.7 ± 6.26
Age
\20 years 1.27 ± 0.23 1.16 ± 0.24 1.03 ± 0.19 60.0 ± 8.89 60.4 ± 6.40 61.3 ± 6.14
C20 years 1.31 ± 0.11 1.23 ± 0.06 0.95 ± 0.19 60.2 ± 8.27 60.6 ± 7.10 61.3 ± 6.64
Education
Secondary 1.31 ± 0.15 1.16 ± 0.26 1.04 ± 0.21 60.5 ± 7.81 61.3 ± 5.32 62.2 ± 5.04
College 1.25 ± 0.25 1.22 ± 0.11 0.95 ± 0.17 59.5 ± 9.70 58.3 ± 7.92 60.2 ± 7.50
Duration of T1DM
\7 years 1.31 ± 0.11 1.14 ± 0.25 0.99 ± 0.22* 58.8 ± 6.47 59.6 ± 4.78 60.7 ± 4.40
C7 years 1.25 ± 0.28 1.23 ± 0.13 1.02 ± 0.15 61.6 ± 10.6 61.5 ± 8.26 62.1 ± 7.90
Overall total 1.28 ± 0.20 1.18 ± 0.21 1.00 ± 0.19 60.1 ± 8.62 60.5 ± 6.55 61.3 ± 6.22
Values are presented as mean ± standard deviation. Groups compared by t test and Tukey’s post hoc test
T1DM type 1 diabetes mellitus
* P\0.05 considered signiﬁcant
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glycemic control among patients with T1DM.
Findings of various studies differ with respect to
the capability of insulin pump to sustain lower
glycemic levels during the first 6–12 months
[16]. A recent seven-year follow-up study
reported that the mean difference in HbA1c
levels between insulin pump and non-insulin
pump users was 0.6% [17]. This level of change
is clinically significant, since the diabetes
control and complications trial (DCCT) has
described reductions in microvascular
complications of 21–49% with every 1%
reduction in HbA1c. Another study has
observed equal improvement in HbA1c for
both male and female patients after 6 months
of insulin pump therapy, but after 12 months
they observed improvement only for male
patients [18]. Furthermore, they found that
the mean HbA1c level at initiation of insulin
pump therapy was 8.7% and declined to a nadir
of 7.5% 6-month post-initiation. This increased
over time (range 7.8–8.2%) but remained lower
than the pre-insulin pump HbA1c level. Also,
shorter duration of diabetes prior to CSII
initiation, presence of an emotional disorder, a
record of missed clinic appointments, and being
a current and active smoker were predictors of
higher HbA1c on CSII [8] On the other hand,
several findings including the DCCT have
confirmed that, compared to MDI treatment,
CSII can deliver better glycemic control with a
lower risk of severe hypoglycemia and lower
weight gain [19, 20]. In contrast to the above
studies, a pilot trial in 2003 in patients aged
12–35 years reported that there was no
significant difference in glycemic control
between CSII and MDI treatments from the
onset of diabetes [21]. It is clear that a tighter
HbA1c goal may have been easier to accomplish
with CSII, thereby distinguishing in efficiency
between the two treatment approaches.
Regarding insulin doses, we found that female
patients and those who have shorter duration of
diabetes mellitus had lower insulin necessity
compared to baseline; this is a common finding
in many other studies [20, 22, 23].
Fig. 2 Impact of insulin pump therapy on glycemic
control. Values are presented as mean ± standard deviation.
Groups compared by t test and Tukey’s post hoc test.
*P\0.05 considered signiﬁcant. DM diabetes mellitus,
HbA1c hemoglobin A1c, yrs years
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Importantly, our study found that the
frequency of hypoglycemic events was
generally lower at 6 months among the study
population when compared to the baseline.
Furthermore, significant decreases were found
among female patients and those who had a
shorter duration of T1DM. Insulin pump
therapy has the benefits of providing both
lower doses of insulin and variable basal doses.
As a result, it may offer a lower risk of
hypoglycemia among patients with T1DM.
Numerous studies have suggested that the risk
of hypoglycemia is reduced among the insulin
pump users [24]. Despite the general benefits,
insulin pumps are not applicable for all
patients, costing several thousand Riyals for
the pump itself and incurring further costs for
monthly supplies [24–26].
The major limitations of this study include a
relatively small sample size, a limited number of
risk factors investigated, limited social and
demographic factors examined, and the fact
that the study was performed at a single center.
Furthermore, there was no control group with
which to compare the study group and so the
results may not be generalizable to real-world
situations. More studies on a larger scale are
needed to address these limitations. Despite the
limitations, the study delivers valuable data for
insulin pump therapy and treatment satisfaction
among patients with T1DM in Saudi Arabia.
CONCLUSIONS
While MDI is a feasible option for insulin
delivery, the use of insulin pumps should also
be considered for patients with T1DM as it was
shown to increase patient treatment
satisfaction, decrease the frequency of
hypoglycemia and hyperglycemia, and reduce
HbA1c levels.
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